Exploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
Read MoreExploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASHNAFLD and Cardiovascular Diseases: What is The Link?
Recent research into non-alcoholic fatty liver disease (NAFLD) has noted its distinct association with cardiovascular diseases (CVDs).
Read MoreNAFLD and Cardiovascular Diseases: What is The Link?Examining the Role of Abnormal Mitochondrial in Fatty Liver Diseases
Mitochondria play a pivotal role in numerous features of hepatic function, driving processes such as substrate metabolism, energy production through cellular signalling, and biotransformation of xenobiotics.
Read MoreExamining the Role of Abnormal Mitochondrial in Fatty Liver DiseasesInsights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?
The growing global prevalence of metabolic diseases, e.g. hypertension, type 2 diabetes mellitus (T2DM), hyperlipidaemia, obesity, and non-alcoholic fatty liver disease (NAFLD), accounts for a significant proportion of this burden.
Read MoreInsights Into the Trends and Global Burden of Metabolic Diseases: What Does the Data Say?NIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?
At-risk non-alcoholic steatohepatitis (NASH) is defined as NASH with NAFLD activity scores (NAS) ≥4 and significant fibrosis (F ≥ 2) diagnosed via histological scoring of liver biopsy.
Read MoreNIS2+™: an effective blood-based test for the detection of at-risk NASH in older adults?Are Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus (T2DM).
Read MoreAre Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Read More“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash TrialsPPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical Data
Non-alcoholic steatohepatitis (NASH) is characterised by complex interactions between intricate intra- and extra-hepatic drivers, encompassing numerous metabolic, inflammatory, vascular, and fibrogenic pathways.
Categories: PPAR Articles, NASH Biomarker, Pathophysiology Articles, Management Articles
Read MorePPAR-modulating Drugs For Nash: Lessons Learned From Pre-clinical And Clinical DataAn exploration of MAFLD’s clinical utility
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Read MoreAn exploration of MAFLD’s clinical utilityA brief introduction to the most promising pharmacological agents for NASH
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
Read MoreA brief introduction to the most promising pharmacological agents for NASHLifestyle interventions in NAFLD: what does the evidence say?
Despite an estimated global prevalence of 38%, no pharmacotherapy has yet been approved for non-alcoholic fatty liver disease (NAFLD).
Read MoreLifestyle interventions in NAFLD: what does the evidence say?NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
Read MoreNASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds